

FDA Registration Trials

Aisha Shah CRP Information Meeting, Conducting FDA Registration Trials

November 1, 2018

Goals

- Registration Trial Considerations
- DTL and RCR
- AE Submissions
- Essential Documents
- Protocol Training
- Auditing and Monitoring
- PI Oversight



REGISTRATION TRIAL CONSIDERATIONS





Alliance and NCI Initiatives: IND/NDA Trials

- Initiatives and Process Changes Implementation 2017-2018
- Improve regulatory authority inspection readiness; implement risk-based monitoring approach
 - Centralized Monitoring
 - Audits with TSDV in Rave
 - Centralized Delegation of Tasks Log (DTL)
 - Centralized Registration and Credential Repository (RCR)
 - CTEP-AERS/Rave Integration
- Alliance standardized approach to registration trials for all pharmaceutical partners

Delegation of Tasks Log (DTL) – What is it?

- NCI to focus on registration trials with central DTL
- Online application by CTSU that is used to define and maintain site personnel listing and their roles/responsibilities
- Via CTEP's Registration & Credential Repository (RCR)
 - Clinical Investigator per protocol
 - Study team per protocol per site
 - Verifies qualifications of study personnel e.g. ICF, H&P, eligibility, toxicity, data entry, etc



Delegation of Tasks Log (DTL) – *Why?*

- Ensures that there are no gaps at the site-level per FDA requirements (DTL is complete before enrollment)
- DTL + registration documents from RCR to create Study Site Registration Packet
 - Registration types Investigator, Non-Physician Investigator, Associate Plus, Associate, Associate Basic
 - Documentation that responsibilities are delegated to qualified personnel



Protocol-specific training

Delegation of Tasks Log (DTL) – Why?

- Audit Per CTMB guidelines (August 2017), The auditor will review the log to evaluate appropriate implementation and maintenance
- Deficiencies:
 - Critical any finding identified before or during an audit that is suspected to be fraudulent activity
 - Major performing tasks not assigned to individual, failure to keep DTL current, individual not listed on DTL, etc



Lesser - other

Delegation of Tasks Log (DTL) – Who?

- Site staff responsible for conduct of protocol leading submitted study data
- Clinical Investigator (CI) responsible for overseeing the conduct of the protocol at the site. Must have active CTEP registration w/ investigator-type & be on a participating site roster



Delegation of Tasks Log (DTL) – *Who?*

- Infusion nurses?
- Lab personnel?
 - The DTL is designed to capture individuals that significantly contribute to the protocol data at the site in the general task areas outlined on the DTL.
 - There is no formal definition of 'significant contributor', but guidance provided by the FDA on completion of the Form FDA 1572 can be found at *https://www.fda.gov/downloads/RegulatoryInformation/ Gui dances/UCM214282.pdf*
 - In general, hospital staff providing ancillary or intermittent routine care are not considered significant contributors.

Registration & Credential Repository (RCR)

- Self-service online registration application for study personnel
 - FDA Form 1572
 - Registration Types require different regulatory documentation – 1572, FDF, NCI Biosketch (education training, certification, license), CV, HSP & GCP training
 - Allows access to CTEP applications, e.g. Rave, OPEN, etc
 - DTL access for site/protocol maintenance





Adverse Event Submission Requirements for Registration Trials

Shauna Hillman

CRP Information Meeting, Conducting FDA Registration Trials

November 1, 2018

AE Submission Requirements for Registration Trials


• Changes

- Instead of reporting the maximum grade that occurred during the treatment cycle, all changes in grade must be reported
- Additions
 - Verbatim term
 - Start date of the AE
 - End Date of the AE
 - On-going status
- AE user guide is available on the CTSU website
 - Covers persistent, intermittent and recurrent AEs



Example of Link to User guide

Link is Available for Cabinet-Trial A021602





CTSU Website

	E			⊠ <u>Hor</u>	ne <u>Contact</u> <u>Feedb</u>		Log Out : 6.9.2.3
	auna Lynn	e Hillman as LPO User 🔻 . Your password will expire in 61 days.			for		Go!
🛠 Home Protocols 🏠 Dashboard Regula	itory -	OPEN Data Management▼ Auditing & Monitoring▼ RUMS▼	Delegation L g -	Resources -	Coll boration		
Resources Browser	2	Delegation of Tasks Log (DTL) Fact Sheet 🐅	01-Dec-2017	PDF	21-Dec-2017	No	~
Search: 🥑 G0	3	DTL Master Task List 🦗	16-Mar-2018	PDF	22-Mar-2018	No	
Here and the second sec	4	Medidata Patient Cloud ePRO Fact Sheet 🐅	02-Jun-2017	PDF	11-Oct-2017	No	
Experimental Therapeutics Clinical	5	National Coverage Analysis - CTSU Initiative Slides 🙀	20-Apr-2016	PDF	10-Aug-2016	No	
Trials Network (ETCTN) Program	6	Regulatory Submission Portal - Quick Start Guide	14-Dec-2016	PDF	14-Dec-2016	No	
CTSU Operation Information CTSU Operation & Reference CTSU Operation & Reference	7	CTSU Overview PowerPoint Presentation 🐅	15-Jun-2016	PDF	16-Jun-2016	No	
	8	CTSU Dashboard Management 🙀	06-Jul-2015	PDF	07-Aug-2015	No	
	9	CTSU Dashboard- Using Filters 🙀	07-Aug-2015	PDF	07-Aug-2015	No	
Der Guides Contract Resources Contract Resources	10	NCTN Per Case Management Funding Information For Sites 🜟	21-Sep-2015	PDF	22-Sep-2015	No	
<u>Researcher Resources</u> <u>Educational Multimedia</u>	11	Instructions for Getting Started With the CTSU	25-Jul-2017	PDF	14-Sep-2017	No	
<u>Site Advisory Panel</u>	12	NCTN Implications for Sites - Slide Set 🖕	20-Feb-2014	PDF	20-Feb-2014	No	
<u> Translated Short Form Consents</u> <u> Provenue Restfolie</u>	Guid	elines & Proceed					
	1	CTEP Guidance for Recording Adverse Event Start and En- Date in Rave	01-Feb-2018	PDF	20-Mar-2018	No	
Glossary and Acronyms	2	Site memory in the labor of the second star Delinquency	08-Feb-2018	PDF	09-Feb-2018	No	
	3	Participation and Crediting Rules 🖕	Not Applicable	Web Link	18-Aug-2017	Not Applicable	
	4	New Regulatory Requirement: IRB Number 📥	20-May-2016	PDF	20-May-2016	No	
	5	NCI National Clinical Trials Network (NCTN) Process for Network Study Champions	22-Apr-2016	PDF	19-May-2016	No	~



Rave – CTEP-AERs Integration

- Purpose: Synchronize routine and expedited Adverse Event (AE) data collection
- Purpose: Provide the site with guidance about whether an AE does/does not need to be submitted as a Serious AE in an expedited fashion
- Required for all trials where CTEP holds the IND starting October 2017
 - Implemented in A031501, A021502, A091605, A021602



Rave - CTEP-AERs Integration

- Main Changes
 - The timing of AE reporting
 - AE data must now be first reported in Rave
 - All updates to AE data must be first made in Rave, then resubmitted for rule evaluation
 - All AEs > grade 0 must be sent for rule evaluation



Rave - CTEP-AERs Integration

- Both solicited and "other" AEs are reported on the same form
- The report period end date should only be recorded when the cycle is complete as this drives querying
- An Expedited Reporting Evaluation Form must be submitted to send all AEs recorded on the AE form for rule evaluation to determine if any need to be reported in an expedited fashion via CTEP-AERs



All fields required for rule evaluation are identified with a red asterisk

The site should leave report period end date missing until after completion of the entire cycle and form

	* Cycle (deri	ved)																			
	* Start date o	of <u>first cour</u>	se/cycle (derived) ?																		1 Sep 201
	* Start date o	of <u>this cour</u>	se/cycle																		6 Sep 20
	Reporting pe								1												
			complete this field aft om System (06 Sep 2)		events have bee	en ent	ered f	for this cyc	le.									Entry	/ Error	~	🗸
	Ö			,																	
		_																			
	REMINDER:	: Dependii ou are alre	ng on your settings i eady viewing the ent	in Rave, this	table may be pa	aginat	ed. If	the optio	ns are available	, clicl	k on Paginate a	nd select Sh	iow Al	I Lines or	click on the nur	neric page nu	mber	s at the bottom r	ight corne	r of the tab	le. If these optic
			sury viewing the ent		1	1	1	1		1	1	1	1	1	1	1		1			
	Verbatim term		*Adverse event term (CTCAE v4.0)	*Adverse event evaluated this cycle?	*Adverse event (grade) grade description (first 120	AE start date			Attribution to study intervention (if grade > 0)	None	Hospitalization	Life- threatening	Death	Disability	Congenital anomaly/birth defect	Required intervention ?	Othe	SAE report recommended (derived)	* AE entry date (derived)	*Time zone (derived)	Adverse event ((CTCAE v4.0 (derived)
				D	characters)																
	_		Hypothyroidism	Pending	-	-	-	_	_									-	_	_	Hypothyroidism
_	-	+	Abdominal pain	Pending	-	-	-	-	_									-	_	-	Abdominal Pain
	-		Constipation	Pending	-	-	-	-	-									-	-	-	Constipation
	-	-	Nausea	Pending	-	-	_	_	_									-	_	_	Nausea
	_		Fatigue	Pending	-	_	_	_	_									-	_	_	Fatigue
_	-		Anorexia	Pending	-	_	_	-	_									_	_	-	Anorexia
	_	\checkmark	Cough	Pending	_	_	_	_	_									_	_	_	Cough
	_	\checkmark	Dyspnea	Pending	_	_	_	_	_									_	_	_	Dyspnea
	Pt came in with fever				(1) 38.0 - 39.0 degrees C	6												No	06 Sep 2017 06	Eastern Standard	

<u>Do not</u> respond to query, it will go away automatically when the report period end date is added. <u>Please leave as a</u> <u>reminder that the form is not complete</u>.

* Cycle (derived)

* Start date of first course/cycle (derived)?

* Start date of this course/cycle

Reporting period end date?

? Reminder: Please complete this field after all adverse events have been entered for this cycle. Opened To Site from System (06 Sep 2017)

Q.

This field is derived from the AE form for cycle 1, if missing enter on the cycle 1 AE form

* Cycle (derived)

* Start date of first course/cycle (derived)

* Start date of this course/cycle

Ve ter	de "Pe	AE evaluated is defaulted to "Pending" and must be updated when AE is evaluated									start, es an oing us ai v, ong us is	id re goin		su ev sr re	After AE is submitted for rule evaluation the AE specific recommendation					
REN NDER:	AE	dicator is sol	icite	ed	ſ			ns are available,	, click	≺on Paginate ar	nd select Sh		deri on p AE s	ved orese stop	base ence date	0	f	/		ound he
avaiable, yo	ou alle alle	eady viewing the enti	re tab.e.							-										
	Solicited (derived)	*Adverse event term (CTCAE v4.0)	*Adverse event evaluated this cycle?	*Adverse event (grade) grade description (first 120 characters)		End date	AE ongoing	Attribution to study intervention (if grade > 0)	None	Hospitalization	Life- threatening ?	Death ?	Disability	Congenital anomaly/birth defect ?	Required intervention ?	Othe	SAE report recommended (derived)	* AE entry date (derived)	*Time zone (derived)	Adverse event term (CTCAE v4.0) (derived)
	(derived)		event evaluated	event (grade) grade description (first 120	AE start	End date	AE ongoing	study intervention (if	None		Life- threatening ?	Death		Congenital anomaly/birth defect ?	Required intervention	Other	recommended	entry date	zone	(CTCAE v4.0)
	(derived)	term (CTCAE v4.0)	event evaluated this cycle?	event (grade) grade description (first 120	AE start	End date	AE ongoing _	study intervention (if			threatening			anomaly/birth defect ?	intervention		recommended	entry date	zone	(CTCAE v4.0) (derived)
	(derived)	term (CTCAE v4.0) Hypothyroidism	event evaluated this cycle? Pending	event (grade) grade description (first 120	AE start	End date	AE ongoing - -	study intervention (if			threatening			anomaly/birth defect ?	intervention ?		recommended	entry date	zone	(CTCAE v4.0) (derived) Hypothyroidism
	(derived) ✓ ✓	term (CTCAE v4.0) Hypothyroidism Abdominal pain	event evaluated this cycle? Pending Pending	event (grade) grade description (first 120	AE start	End date	AE ongoing - - -	study intervention (if			threatening ?			anomaly/birth defect	intervention ?		recommended	entry date	zone	(CTCAE v4.0) (derived) Hypothyroidism Abdominal Pain
	(derived)	term (CTCAE v4.0) Hypothyroidism Abdominal pain Constipation	event evaluated this cycle? Pending Pending Pending	event (grade) grade description (first 120	AE start	End date	AE ongoing - - - -	study intervention (if			threatening ?			anomaly/birth defect 2	intervention ?		recommended	entry date	zone	(CTCAE v4.0) (derived) Hypothyroidism Abdominal Pain Constipation
	(derived) ✓ ✓ ✓ ✓	term (CTCAE v4.0) Hypothyroidism Abdominal pain Constipation Nausea	event evaluated this cycle? Pending Pending Pending Pending	event (grade) grade description (first 120	AE start	End date	AE ongoing	study intervention (if			threatening			anomaly/birth defect	intervention ?		recommended	entry date	zone	(CTCAE v4.0) (derived) Hypothyroidism Abdominal Pain Constipation Nausea
	(derived)	term (CTCAE v4.0) Hypothyroidism Abdominal pain Constipation Nausea Fatigue	event evaluated this cycle? Pending Pending Pending Pending	event (grade) grade description (first 120	AE start	End date	AE ongoing - - - - - -	study intervention (if			threatening			anomaly/birth defect 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	intervention		recommended	entry date	zone	(CTCAE v4.0) (derived) Hypothyroidism Abdominal Pain Constipation Nausea Fatigue
	(derived)	term (CTCAE v4.0) Hypothyroidism Abdominal pain Constipation Nausea Fatigue Anorexia	event evaluated this cycle? Pending Pending Pending Pending Pending	event (grade) grade description (first 120	AE start	End date	AE ongoing - - - - - - - - - -	study intervention (if			threatening			anomaly/birth defect 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	intervention ?		recommended	entry date	zone	(CTCAE v4.0) (derived) Hypothyroidism Abdominal Pain Constipation Nausea Fatigue Anorexia

Expedited Reporting Evaluation Form

A query fires anytime a new AE is entered or an existing AE is updated. Check the checkbox and save the form to submit the AE for rule evaluation

If a query is present on the AE form, you will NOT be able to send the AE for rule evaluation until after the query is resolved, exception is the query that fires on the report period end date

Subject: 91 13876 Page: Exp dited Reporting Evaluation - Treatment 02 Form Instructions ? A d 2lay is expected when the	TEP-AERS	Recommendation provided here and is populated after form is submitted, if the site disagrees they may override	pentered on the same ticket
Course/Cycle # (derived)			2 🕉 K
	vents have to be evaluated to determine if expedited reporting is save the form to determine if expedited reporting is recommended.		Entry Error V 🗠 🍞 🖇
Recommended action for report (derived) An expedited report is NOT recommended If the below to move to CTEP-AERS to complet the ex- Opened To Site from System (07 Sep 20 √) A Click this link to complete the safety report			NONE 🔮 🖗
Report ID (derived)			REP0028057 🥑 🕱

Rave – CTEP–AERs Integration

- All Alliance trials must use the new AE Form
 - verbatim term, AE start date, AE end date and ongoing status fields required for Registration trials only
 - All changes in AE grades must also be captured for Registration trials only
 - Integration required for all trials where CTEP holds the IND

Rave – CTEP–AERs Integration: Misc Notes

 The sticky notes found on the Expedited Reporting Evaluation Form are for instructional purposes only and there is no way to remove them from your Rave Task Summary

Recommended action for report (derived)

An expedited report is NOT recommended. If the Investigator believes an expedited report is warranted, use the link below to move to CTEP-AERS to complete the expedited report.[QC019] Opened To Site from System (15 Aug 2018)

Click this link to complete the safety report

 The AE Start Date cannot be before the start date of cycle 1, if a pre-existing condition, enter the start date of cycle 1

Rave – CTEP–AERs Integration: Misc Notes

- You do not have to wait until all solicited AEs are evaluated to run the rule evaluation, the form is designed for you to evaluate AEs in real time
- If all AEs are reported, you do not have to submit each AE for rule evaluation, saving the Expedited Reporting Evaluation Form will result in all AEs on the AE form being evaluated.



Any Questions?



Essential Documents at Sites (ICH E6, Section 8) –

- 1. Investigator Brochures
- 2. Protocol and amendments
- 3. ICF (and any other study info distributed to patient)
- 4. Subject recruitment info
- 5. IRB/Independent Ethics Committee
- 6. Investigator CVs
- 7. Lab certification/accreditation
- 8. IP handling instructions & shipping records & DARF



Essential Documents at Sites (ICH E6, Section 8):

- 1. Monitoring letters
- 2. Correspondences b/w IRB & Institution
- 3. AE/SAE/SUSAR/UPIRSO sitespecific SOPs, if applicable
- 4. Protocol-specific training
- 5. Screening/enrollment logs, per site
 SOP

Essential Documents – Don't Forget:

- Sites should also have copies maintained of:
- 1. RCR 1572, CV, License, FDF
- 2. **DTL**
- Regulatory Support System (RSS) regulatory approval, protocol amendments, continuing renewal, site termination letter from IRB, protocol-specific-training, +/- ICF templates





National Institutes of Health National Cancer Institute Center for Cancer Research Bethesda, Maryland 20892

Protocol Review Log

Protocol #:	Protocol Title:

The individuals listed below have reviewed the protocol with the PI or designee and understand their roles and responsibilities.

Name (Please Print or Type)	Role	Signature	Date	PI/Designee Signature	Date



Protocol Training

- Importance of maintaining log?
 - Protocol amendments
 - Staffing changes at the site
- FDA-inspection readiness
- Do you know your site's SOP?
 - Alternative/Back-up documentation
- Webinars for Alliance registration trials posted to Alliance website





Auditing & Monitoring

• Monitoring

- Overseeing progress of a clinical trial and ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and regulatory requirements
- Auditing
 - Systematic & independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted, and the data were recorded, analyzed, and accurately reported according to the protocol, sponsor's SOPs, GCP, and regulatory requirements



Monitoring

- Mandatory per federal regulations (21 CFR812.3 (j), 812.25, 812.40, and 312.50)
- During a US regulatory audit, FDA has access to monitoring reports and their associated action items
 - Importance of addressing action items on a monitoring letter/report in a timely fashion



Monitoring

- Depending on the study-specific monitoring plan, the following is routinely monitored:
 - Informed consent Documents
 - Eligibility criteria
 - Protocol compliance
 - Source data verification for data accuracy
 - Query resolution
 - AEs occurrence and reporting
 - IP accountability
 - Essential documents
 - Clinical Investigator (CI) & IRB oversight

 CI is adequately informed of responsibilities to recruit eligible subjects & collect high quality data



Central Monitoring to Support Registration Trials

Shauna Hillman

CRP Information Meeting, Conducting FDA Registration Trials

November 1, 2018

Alliance Central Monitors

• Tiffany Schafer



• Sara Goodman





Central Monitoring

- Introduction
 - Central Monitoring (CM) is performed by Lead Protocol Organizations (LPOs) to ensure protocol compliance by sites
 - It consists of remote review of source documents against data entered in Rave
 - The Source Document Portal (SDP) is an application on the CTSU website in the Auditing & Monitoring tab used to support the collection of source documents for CM review



Central Monitoring-Current Status

- The CTSU SDP is not in use for any current Alliance trials
- Central Monitoring (CM) is being conducted for the following trials
 - A031501-Ambassador
 - A021502-Atomic
 - A021602-Cabinet
 - A041701-Future trial
- CM is currently being facilitated by uploading source documents on the Source Document Form within Rave

Example of Baseline Source Document Form for Atomic Trial

企 ()A021502

Cycle

m Ba

Baseline Supporting Documentation: Baseline

Subject: 9116633 Page: Supporting Documentation: Baseline - Baseline

Attachment Serial # of document Date of assessment Report type Specify report type (max file size 10 MB) 1 09 Feb 2018 H & P A021502 HP 2.9.18 Redacted.pdf 1 2 2 09 Jan 2018 Colonoscopy Report A021502 Colonoscopy 1.9.18 Redacted.pdf 3 3 09 Jan 2018 Pathology report from colonoscopy A021502 Path 1.9.18 Redacted.pdf 4 4 19 Jan 2018 Pathology report from surgery A021502 Path 1.19.18 Redacted.pdf 5 5 19 Jan 2018 Operative report A021502 Op note 1.19.18 Redacted.pdf 6 6 CT Ab/Pelvis 12 Jan 2018 Imaging report A021502 CT AbPel 1.12.18 Redacted.pdf 7 7 19 Jan 2018 Same Path report from Operation dMMR testing results A021502 Path 1.19.18 Redacted.pdf 8 8 09 Feb 2018 Informed Consent (redacted signature page) A021502 Consent Redacted.pdf 9 9 15 Feb 2018 Chest CT A021502 CT Chest 2.15.18 Redacted.pdf Imaging report 10 10



Source Document Reminders

- Redact all source documents before uploading
- The Informed Consent Document should include all indications to the optional correlative studies
- When 'yes' is provided for the disease assessment question, you must provide source documentation (imaging, biopsy, etc.)



Source Document Reminders

- Source documents required for treatment may not be required for every cycle of treatment
 - Current requirements for Atomic

Treatment	Treatment (Intervention)	Agent name
(first 3 cycles ¹ ; all cycles ²)		Dose level
		Units of measure
		Dose (total)
		Units of measure
		Was protocol treatment modified?
		Was protocol treatment omitted?
		Was protocol treatment delayed?
		Start date
		Stop date
	Treatment (Intervention): Dose	Dose modification reason
	Modifications, Omissions and Delays	Dose omission reason
		Dose delay reason



Where to Find the Needed Source Documents

Data Submission Schedule for A021502 & A021602, protocol for A031501

Data Submission Schedule for A021502:

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

SOURCE DOCUMENTATION REQUIREMNTS FOR MONITORING

The following data and documents will be reviewed through central/on-site data monitoring and source data verification (SDV) activities.

Domain	CRF	Data Fields/Section	Acceptable Source Documents
Informed Consent	Informed Consent ¹	Date of signature ³	Informed Consent Document
		Signature page ³	
	Informed Consent ²	Entire document	
Eligibility ¹	OPEN Registration Worksheet	All fields	Path report
	On-study	Description of Primary Disease Section	IHC report
		Mismatch Repair Testing Section	Operative report
		Patient History Section (excluding NSAID	Radiology report
		usage)	Colonoscopy report
		ECOG Performance Status	Lab report (for registration eligibility)
		Correlative Studies Section	Clinic note
		Correlative bildates because	Other relevant report
Treatment	Treatment (Intervention)	Agent name	Relevant medical record (e.g., clinic note, other)
(first 3 cycles ¹ ; all cycles ²)		Dose level	,,
		Units of measure	
		Dose (total)	
		Units of measure	
		Was protocol treatment modified?	
		Was protocol treatment mounted?	
		Was protocol treatment delayed?	
		Start date	
		Stop date	
	Treatment (Intervention): Dose	Dose modification reason	
	Modifications, Omissions and Delays	Dose omission reason	
	Wodifications, Offissions and Delays	Dose delay reason	
Off Treatment 2	Off Treatment	All fields	Relevant medical record (e.g., clinic note, other)
Disease Assessment ¹	Patient Status: Baseline.	Survival Status Section	Radiology report (conventional CT and MRI or chest x-ray)
Disease Assessment	Patient Status: Dasenne, Patient Status: Treatment.	Disease Status Section	Lab report
	Patient Status: Treatment, Patient Status: Clinical Follow-up,	New Primary Section	Colonoscopy report
	Patient Status: Chincal Follow-up, Patient Status: Survival Follow-up	New Filmary Section	Relevant medical record (e.g., clinic note, other)
Disease Recurrence ¹	Notice of Recurrent Disease	All fields	Radiology report (conventional CT and MRI or chest x-ray)
Disease Recurrence.	Notice of Recurrent Disease	All fields	Lab report
New Primary ¹	N.C. ON D.	A 11 / 11	Colonoscopy report
	Notice of New Primary	All fields	Radiology report (conventional CT and MRI or chest x-ray)
			Lab report
1			Colonoscopy report
Adverse Events ²	Adverse Events	All fields	Relevant medical record (e.g., clinic note, other)
	Late Adverse Events		
Consent Withdrawal ²	Consent Withdrawal (all types)	All fields	Relevant medical record (e.g., clinic note, other)

1 Central and on-site monitoring

² On-site monitoring only

³ For Central Monitoring: De-identified Informed Consent Document (ICD): Last page of signed and dated ICD (including page/s with options indicated by patient for additional studies). Patient's full signature should be redacted but date should be retained.


Data Submission Schedule SD Requirements for Monitoring

Data Submission Schedule for A021502:

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

SOURCE DOCUMENTATION REQUIREMNTS FOR MONITORING

The following data and documents will be reviewed through central/on-site data monitoring and source data verification (SDV) activities.





Future Initiatives

- Alliance is in the process of selecting a future trial to implement the CTSU SDP
- There are no plans to implement the SDP for trials that are already activated
- Alliance is working out how to use the SDP to facilitate both source documents needed for central monitoring and source documents needed for eligibility reviews and case
 evaluations





Any Questions?



Auditing

- Quality assurance function
- Auditors can assess a wider study sample than monitors and can help evaluate trends at various levels
 - single or multiple sites and/or multiple studies
 - trial vendors/sponsors
- Evaluate compliance to recognized standards
 - FDA's Code of Regulations
 - International Conference on Harmonization
 - International Standards Organization
 - SOPs



Auditing

- Compliance snapshot
- Can assist in determining effectiveness of:
 - Monitoring
 - importance of addressing action items on monitoring reports in a timely fashion
 - Study team
- Manage non-compliant sites
- Assess inspection readiness



Investigator Oversight

- How often do you meet with your investigator?
- Are routine meetings established?
- Process for obtaining signatures/assessments?



Investigator Oversight – How to demonstrate?

- Timely signatures on source documents
 - Diagnostic procedures
 - Recist reads
 - Lab results
 - Eligibility criteria
 - Treatment authorization
- DTL appropriate and qualified staff delegation
- SAE/SUSARs evaluated and submitted in a timely manner




Investigator Oversight – How to demonstrate?

- Feedback from the FDA suggests that they are concerned with one Clinical Investigator covering multiple sites and protocols
 - No hard rule as to how many sites/protocols a CI may cover
 - May be a reason for triggering an audit



FDA Inspection Readiness

- On-going state of effectiveness and suitability monitored through periodic review an monitoring of compliance
 - Not a preparation activity
 - Requires Investigators and management to be actively involved and committed to culture of compliance
- FDA Bioresearch Monitoring (BIMO) Inspection Program
 - Protects the rights, safety, and welfare of human research subjects



FDA Inspection Focus at Sites:

- CI oversight
- Site management
- Data
- Investigational product (IP) management
- Adverse Events



FDA Inspection Process:

- 1. Notification of inspection via FDA Form 482
- 2. Opening meeting
- 3. Interview of site staff
- 4. Review of study-related/source documents
- 5. Exit meeting
 - Review findings
 - Address issues or concerns
- 6. Response to inspection, as needed



FDA Inspection – What to do if issued FDA Form 482?

- Alliance and/or pharmaceutical partner will:
 - Provide additional instructions & guidance for preparing
 - Provide a single point of contact (SPoC) at Alliance for any issues that may arise during the inspection
 - Site should also provide daily report to Alliance SPoC

• SPoC will assist in preparing responses to the inspection findings, if needed

FDA Inspection – Role of Investigator/ Site

- Ensure availability of staff during inspection
 - Alert other staff of section, so that they know to avoid lingering in areas hosting the inspection & to watch conversations near inspectors
- Ensure availability of study-related records & provide copies to HA as requested
- Answer questions regarding your role
- At the end of each day, request a summary from the inspector
 - Forward summary to Alliance SPoC
 - Respond to any inspection findings, as needed




FDA Inspection – Role of Alliance

- Assign SPoC to site
- Provide daily status report to pharmaceutical partners
- Provide ongoing support to site/investigator before, during, and after



FDA Inspection – *Tips for Interacting with Inspectors*

- When answering questions:
 - Honestly
 - Be concise & clear only answer the question asked
 - Don't argue with inspector
 - Don't answer hypothetical questions
 - Wait until you have heard & understood the whole question



FDA Inspection – *Findings:*

- Criticality determined by deficiencies that:
 - Affects rights, safety, or welfare of subjects
 - Impacts data integrity
 - Indicates systematic problems within the study from the Sponsor
 - Indicates problems with the investigator/site that may impact other studies
- FDA Form 483, Inspectional Observations, documents & communicates concerns disovered during inspections

Forward to Alliance SPoC, immediately!

FDA Inspection – Resources:

- FDA regulatory info for clinical trials: <u>https://www.fda.gov/RegulatoryInformation/G</u> <u>uidances/ucm122046.htm</u>
- FDA Cooperative Research Information Sheet:

https://www.fda.gov/RegulatoryInformation/G uidances/ucm126422.htm

 FDA Bioresearch Monitoring Info: <u>https://www.fda.gov/ICECI/EnforcementActio</u> ns/BioresearchMonitoring/default.htm





Any Questions?

